EVIK Dx Innovations is expanding

The company is exhibiting at AACC Booth #3275

26 Jul 2022
Dora Wells
Clinical Content Editor

EVIK™ Diagnostic Innovations has announced it is expanding as a company and moving its R&D facilities. The new R&D facility will be co-located alongside its production facility in Ottawa. The company is adding equipment to increase capacity and on-boarding new staff to include growing its expertise in formulation characterization. This expansion will allow EVIK to continue improving its custom lyophilization success while providing quick turnaround service to meet the growing demands of its clients.

In addition, its production facility is being upgraded with new, additional automation equipment, allowing the company to efficiently package more unique devices for its clients.

EVIK is a global market leader in custom assay reagent lyophilization for both human and non-human applications. With your custom reagents, whether Ab/Ag. protein, nucleic acid based, or other, the company produces precise, durable, RT stable beads, EVIK DxSpheres™, and packages them almost any way you would like for your custom device or needs.

Daily coverage of AACC by SelectScience can be found by clicking here >>

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags